• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌进展中的肿瘤免疫微环境。

The Tumor Immune Microenvironment in Breast Cancer Progression.

机构信息

Department of Cancer Genetics, Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Radium Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Department of Cancer Immunology, Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Radium Hospital, Oslo, Norway.

出版信息

Acta Oncol. 2024 May 23;63:359-367. doi: 10.2340/1651-226X.2024.33008.

DOI:10.2340/1651-226X.2024.33008
PMID:38779867
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11332517/
Abstract

BACKGROUND

The tumor microenvironment significantly influences breast cancer development, progression, and metastasis. Various immune cell populations, including T cells, B cells, NK cells, and myeloid cells exhibit diverse functions in different breast cancer subtypes, contributing to both anti-tumor and pro-tumor activities.

PURPOSE

This review provides an overview of the predominant immune cell populations in breast cancer subtypes, elucidating their suppressive and prognostic effects. We aim to outline the role of the immune microenvironment from normal breast tissue to invasive cancer and distant metastasis.

METHODS

A comprehensive literature review was conducted to analyze the involvement of immune cells throughout breast cancer progression.

RESULTS

In breast cancer, tumors exhibit increased immune cell infiltration compared to normal tissue. Variations exist across subtypes, with higher levels observed in triple-negative and HER2+ tumors are linked to better survival. In contrast,  ER+ tumors display lower immune infiltration, associated with poorer outcomes. Furthermore, metastatic sites commonly exhibit a more immunosuppressive microenvironment.

CONCLUSION

Understanding the complex interaction between tumor and immune cells during breast cancer progression is essential for future research and the development of immune-based strategies. This comprehensive understanding may pave the way for more effective treatment approaches and improved patients outcomes.

摘要

背景

肿瘤微环境显著影响乳腺癌的发生、发展和转移。各种免疫细胞群体,包括 T 细胞、B 细胞、NK 细胞和髓系细胞,在不同的乳腺癌亚型中表现出不同的功能,既有抗肿瘤作用,也有促肿瘤作用。

目的

本文综述了乳腺癌亚型中主要的免疫细胞群体,阐明了它们的抑制和预后作用。我们旨在概述从正常乳腺组织到浸润性癌和远处转移的免疫微环境的作用。

方法

对免疫细胞在乳腺癌进展过程中的作用进行了全面的文献回顾分析。

结果

与正常组织相比,乳腺癌肿瘤中存在更多的免疫细胞浸润。不同亚型之间存在差异,三阴性和 HER2+肿瘤中浸润水平较高与生存改善相关,而 ER+肿瘤浸润水平较低与预后不良相关。此外,转移部位通常表现出更具免疫抑制性的微环境。

结论

了解乳腺癌进展过程中肿瘤和免疫细胞之间的复杂相互作用对于未来的研究和免疫为基础的策略的发展至关重要。这种全面的理解可能为更有效的治疗方法和改善患者预后铺平道路。

相似文献

1
The Tumor Immune Microenvironment in Breast Cancer Progression.乳腺癌进展中的肿瘤免疫微环境。
Acta Oncol. 2024 May 23;63:359-367. doi: 10.2340/1651-226X.2024.33008.
2
Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.调节性 T 淋巴细胞浸润转移性乳腺癌-独立的预后因素,其随着肿瘤进展而变化。
Breast Cancer Res. 2021 Feb 18;23(1):27. doi: 10.1186/s13058-021-01403-0.
3
Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases.粒细胞免疫浸润对于乳腺癌肝转移的有效形成至关重要。
Breast Cancer Res. 2015 Mar 27;17(1):45. doi: 10.1186/s13058-015-0558-3.
4
The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer.免疫细胞在乳腺组织中的作用及免疫疗法在乳腺癌治疗中的应用。
Clin Breast Cancer. 2021 Feb;21(1):e63-e73. doi: 10.1016/j.clbc.2020.06.011. Epub 2020 Jul 2.
5
Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.自然杀伤细胞种系变异与肿瘤免疫微环境亚型、肿瘤浸润淋巴细胞、免疫治疗反应、临床结局和癌症风险的关联。
JAMA Netw Open. 2019 Sep 4;2(9):e199292. doi: 10.1001/jamanetworkopen.2019.9292.
6
Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.过表达 S100A9 可改善雌激素受体阳性乳腺癌中 NK 细胞功能障碍。
Cancer Immunol Immunother. 2024 May 7;73(7):117. doi: 10.1007/s00262-024-03699-1.
7
Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model.人类乳腺癌肿瘤微环境,以及猫乳腺肿瘤作为潜在的研究模型。
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188587. doi: 10.1016/j.bbcan.2021.188587. Epub 2021 Jul 5.
8
The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting.乳腺癌中的免疫微环境:新辅助治疗环境中的预测和预后作用。
Pathobiology. 2020;87(2):61-74. doi: 10.1159/000504055. Epub 2019 Nov 12.
9
Prognostic Value of Natural Killer Cells Besides Tumor-Infiltrating Lymphocytes in Breast Cancer Tissues.自然杀伤细胞除肿瘤浸润淋巴细胞外对乳腺癌组织的预后价值。
Clin Breast Cancer. 2021 Dec;21(6):e738-e747. doi: 10.1016/j.clbc.2021.02.003. Epub 2021 Feb 16.
10
Decreased expression in breast tumor cells causes NK cell activation and promotes tumor progression.乳腺癌细胞中表达水平降低会导致 NK 细胞激活,并促进肿瘤进展。
Cancer Biol Med. 2024 Mar 25;21(6):513-40. doi: 10.20892/j.issn.2095-3941.2023.0382.

引用本文的文献

1
Subtype- and race-specific variations in the immune landscape of breast cancer: therapeutic implications.乳腺癌免疫格局中的亚型和种族特异性差异:治疗意义
NPJ Breast Cancer. 2025 Jul 24;11(1):78. doi: 10.1038/s41523-025-00799-8.
2
Exploring the landscape of autoimmune disorder-associated genes and their impact on immune microenvironment in breast cancer patients.探索自身免疫性疾病相关基因图谱及其对乳腺癌患者免疫微环境的影响。
Am J Transl Res. 2025 Jun 15;17(6):4733-4743. doi: 10.62347/EANH4082. eCollection 2025.
3
Identification and validation of genes related to stem cells and telomere maintenance mechanisms as biomarkers for breast cancer.

本文引用的文献

1
A spatially resolved single-cell genomic atlas of the adult human breast.成人乳腺的空间分辨单细胞基因组图谱。
Nature. 2023 Aug;620(7972):181-191. doi: 10.1038/s41586-023-06252-9. Epub 2023 Jun 28.
2
Advances in natural killer cell therapies for breast cancer.自然杀伤细胞疗法在乳腺癌治疗中的进展。
Immunol Cell Biol. 2023 Sep;101(8):705-726. doi: 10.1111/imcb.12658. Epub 2023 Jun 6.
3
Neoadjuvant immune checkpoint blockade triggers persistent and systemic T activation which blunts therapeutic efficacy against metastatic spread of breast tumors.
鉴定和验证与干细胞及端粒维持机制相关的基因作为乳腺癌生物标志物
Front Immunol. 2025 Jul 1;16:1618193. doi: 10.3389/fimmu.2025.1618193. eCollection 2025.
4
A Systematic Review of Immune Cell Roles in Breast Cancer Immunotherapy.乳腺癌免疫治疗中免疫细胞作用的系统评价
Cancer Rep (Hoboken). 2025 May;8(5):e70217. doi: 10.1002/cnr2.70217.
5
Development of a prognostic model based on four genes related to exhausted CD8+ T cell in triple-negative breast cancer patients: a comprehensive analysis integrating scRNA-seq and bulk RNA-seq.基于三阴性乳腺癌患者中与耗竭性CD8 + T细胞相关的四个基因构建预后模型:整合单细胞RNA测序和批量RNA测序的综合分析
Discov Oncol. 2025 Feb 3;16(1):114. doi: 10.1007/s12672-025-01812-z.
6
Self-Tumor Antigens in Solid Tumors Turned into Vaccines by α-gal Micelle Immunotherapy.通过α-半乳糖胶束免疫疗法将实体瘤中的自身肿瘤抗原转化为疫苗。
Pharmaceutics. 2024 Sep 27;16(10):1263. doi: 10.3390/pharmaceutics16101263.
7
Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare.《肿瘤学学报》北欧精准癌症医学研讨会2023——融合临床研究与标准医疗保健
Acta Oncol. 2024 Jun 23;63:487-490. doi: 10.2340/1651-226X.2024.24954.
新辅助免疫检查点阻断引发持续和全身性的 T 细胞激活,从而削弱了对乳腺癌转移扩散的治疗效果。
Oncoimmunology. 2023 Apr 13;12(1):2201147. doi: 10.1080/2162402X.2023.2201147. eCollection 2023.
4
Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities.乳腺癌肝转移中的耐药机制:困境与机遇
Mol Ther Oncolytics. 2023 Feb 6;28:212-229. doi: 10.1016/j.omto.2023.02.001. eCollection 2023 Mar 16.
5
Immunotherapy in breast cancer: an overview of current strategies and perspectives.乳腺癌免疫治疗:当前策略与前景综述
NPJ Breast Cancer. 2023 Feb 13;9(1):7. doi: 10.1038/s41523-023-00508-3.
6
Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response.三级淋巴结构对癌症预后和治疗反应至关重要。
Front Immunol. 2023 Jan 11;13:1063711. doi: 10.3389/fimmu.2022.1063711. eCollection 2022.
7
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.早期 ERBB2/HER2 阳性乳腺癌中免疫相关基因表达特征与肿瘤浸润淋巴细胞的预后和预测价值:CALGB 40601 和 PAMELA 试验的相关性分析。
JAMA Oncol. 2023 Apr 1;9(4):490-499. doi: 10.1001/jamaoncol.2022.6288.
8
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.阿替利珠单抗联合基于蒽环类药物的化疗治疗转移性三阴性乳腺癌:随机、双盲、2b 期 ALICE 试验。
Nat Med. 2022 Dec;28(12):2573-2583. doi: 10.1038/s41591-022-02126-1. Epub 2022 Dec 8.
9
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers.BRCA1/2 突变携带者的正常乳腺组织中免疫细胞增多。
Breast Cancer Res Treat. 2023 Jan;197(2):277-285. doi: 10.1007/s10549-022-06786-y. Epub 2022 Nov 16.
10
Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node.原发性乳腺癌、前哨淋巴结和转移性淋巴结中肿瘤细胞与免疫细胞的单细胞图谱。
Breast Cancer. 2023 Jan;30(1):77-87. doi: 10.1007/s12282-022-01400-x. Epub 2022 Sep 21.